Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 23 of 23 entries
Sorted by: Best Match Show Resources per page
Accuracy of delivered airway pressure and work of breathing estimation during proportional assist ventilation: a bench study.

Annals of intensive care

Beloncle F, Akoumianaki E, Rittayamai N, Lyazidi A, Brochard L.
PMID: 27076185
Ann Intensive Care. 2016 Dec;6(1):30. doi: 10.1186/s13613-016-0131-y. Epub 2016 Apr 14.

BACKGROUND: Proportional assist ventilation+ (PAV+) delivers airway pressure (P aw) in proportion to patient effort (P mus) by using the equation of motion of the respiratory system. PAV+ calculates automatically respiratory mechanics (elastance and resistance); the work of breathing...

Cite
Beloncle F, Akoumianaki E, Rittayamai N, et al. Accuracy of delivered airway pressure and work of breathing estimation during proportional assist ventilation: a bench study. Ann Intensive Care. 2016;6(1):30doi: 10.1186/s13613-016-0131-y.
Beloncle, F., Akoumianaki, E., Rittayamai, N., Lyazidi, A., & Brochard, L. (2016). Accuracy of delivered airway pressure and work of breathing estimation during proportional assist ventilation: a bench study. Annals of intensive care, 6(1), 30. https://doi.org/10.1186/s13613-016-0131-y
Beloncle, Francois, et al. "Accuracy of delivered airway pressure and work of breathing estimation during proportional assist ventilation: a bench study." Annals of intensive care vol. 6,1 (2016): 30. doi: https://doi.org/10.1186/s13613-016-0131-y
Beloncle F, Akoumianaki E, Rittayamai N, Lyazidi A, Brochard L. Accuracy of delivered airway pressure and work of breathing estimation during proportional assist ventilation: a bench study. Ann Intensive Care. 2016 Dec;6(1):30. doi: 10.1186/s13613-016-0131-y. Epub 2016 Apr 14. PMID: 27076185; PMCID: PMC4830790.
Copy Download .nbib Format: NLM
Effects of canagliflozin on human myocardial redox signalling: clinical implications.

European heart journal

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C.
PMID: 34293101
Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420.

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects,...

Cite
Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-4960doi: 10.1093/eurheartj/ehab420.
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., Oikonomou, E. K., Reus, E. M., Sayeed, R., Krasopoulos, G., Srivastava, V., Farid, S., Chuaiphichai, S., Shirodaria, C., Channon, K. M., Casadei, B., & Antoniades, C. (2021). Effects of canagliflozin on human myocardial redox signalling: clinical implications. European heart journal, 42(48), 4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Kondo, Hidekazu, et al. "Effects of canagliflozin on human myocardial redox signalling: clinical implications." European heart journal vol. 42,48 (2021): 4947-4960. doi: https://doi.org/10.1093/eurheartj/ehab420
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420. PMID: 34293101.
Copy Download .nbib Format: NLM
Effects of canagliflozin on human myocardial redox signalling: clinical implications.

European heart journal

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C.
PMID: 34293101
Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420.

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects,...

Cite
Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-4960doi: 10.1093/eurheartj/ehab420.
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., Oikonomou, E. K., Reus, E. M., Sayeed, R., Krasopoulos, G., Srivastava, V., Farid, S., Chuaiphichai, S., Shirodaria, C., Channon, K. M., Casadei, B., & Antoniades, C. (2021). Effects of canagliflozin on human myocardial redox signalling: clinical implications. European heart journal, 42(48), 4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Kondo, Hidekazu, et al. "Effects of canagliflozin on human myocardial redox signalling: clinical implications." European heart journal vol. 42,48 (2021): 4947-4960. doi: https://doi.org/10.1093/eurheartj/ehab420
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420. PMID: 34293101; PMCID: PMC8691807.
Copy Download .nbib Format: NLM
Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species.

Nature communications

Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Etienne E, Beauvais A, Samonis G, Kontoyiannis DP, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G.
PMID: 30467313
Nat Commun. 2018 Nov 22;9(1):5015. doi: 10.1038/s41467-018-07301-y.

The original version of this Article contained an error in the spelling of the author Emilien Etienne, which was incorrectly given as Emilien Ettiene. These errors have now been corrected in both the PDF and HTML versions of the...

Cite
Andrianaki AM, Kyrmizi I, Thanopoulou K, et al. Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun. 2018;9(1):5015doi: 10.1038/s41467-018-07301-y.
Andrianaki, A. M., Kyrmizi, I., Thanopoulou, K., Baldin, C., Drakos, E., Soliman, S. S. M., Shetty, A. C., McCracken, C., Akoumianaki, T., Stylianou, K., Ioannou, P., Pontikoglou, C., Papadaki, H. A., Tzardi, M., Belle, V., Etienne, E., Beauvais, A., Samonis, G., Kontoyiannis, D. P., Andreakos, E., Bruno, V. M., Ibrahim, A. S., & Chamilos, G. (2018). Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nature communications, 9(1), 5015. https://doi.org/10.1038/s41467-018-07301-y
Andrianaki, Angeliki M, et al. "Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species." Nature communications vol. 9,1 (2018): 5015. doi: https://doi.org/10.1038/s41467-018-07301-y
Andrianaki AM, Kyrmizi I, Thanopoulou K, Baldin C, Drakos E, Soliman SSM, Shetty AC, McCracken C, Akoumianaki T, Stylianou K, Ioannou P, Pontikoglou C, Papadaki HA, Tzardi M, Belle V, Etienne E, Beauvais A, Samonis G, Kontoyiannis DP, Andreakos E, Bruno VM, Ibrahim AS, Chamilos G. Author Correction: Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species. Nat Commun. 2018 Nov 22;9(1):5015. doi: 10.1038/s41467-018-07301-y. PMID: 30467313; PMCID: PMC6250689.
Copy Download .nbib Format: NLM
Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study.

Germs

Ioannou P, Akoumianaki E, Alexakis K, Proklou A, Psyllaki M, Stamatopoulos E, Koulentaki M, Kondili E, Kofteridis DP.
PMID: 33134207
Germs. 2020 Sep 01;10(3):266-271. doi: 10.18683/germs.2020.1216. eCollection 2020 Sep.

INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening rare disease resulting from the uncontrolled activation of the immune system, leading to unrestrained cytokine release and macrophage activation. It can be either hereditary or acquired due to infections, hematological disease or...

Cite
Ioannou P, Akoumianaki E, Alexakis K, et al. Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study. Germs. 2020;10(3):266-271doi: 10.18683/germs.2020.1216.
Ioannou, P., Akoumianaki, E., Alexakis, K., Proklou, A., Psyllaki, M., Stamatopoulos, E., Koulentaki, M., Kondili, E., & Kofteridis, D. P. (2020). Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study. Germs, 10(3), 266-271. https://doi.org/10.18683/germs.2020.1216
Ioannou, Petros, et al. "Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study." Germs vol. 10,3 (2020): 266-271. doi: https://doi.org/10.18683/germs.2020.1216
Ioannou P, Akoumianaki E, Alexakis K, Proklou A, Psyllaki M, Stamatopoulos E, Koulentaki M, Kondili E, Kofteridis DP. Hemophagocytic lymphohistiocytosis syndrome associated with Epstein-Barr infection in an immunocompetent patient. A case study. Germs. 2020 Sep 01;10(3):266-271. doi: 10.18683/germs.2020.1216. eCollection 2020 Sep. PMID: 33134207; PMCID: PMC7572213.
Copy Download .nbib Format: NLM
Effects of canagliflozin on human myocardial redox signalling: clinical implications.

European heart journal

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C.
PMID: 34293101
Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420.

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects,...

Cite
Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-4960doi: 10.1093/eurheartj/ehab420.
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., Oikonomou, E. K., Reus, E. M., Sayeed, R., Krasopoulos, G., Srivastava, V., Farid, S., Chuaiphichai, S., Shirodaria, C., Channon, K. M., Casadei, B., & Antoniades, C. (2021). Effects of canagliflozin on human myocardial redox signalling: clinical implications. European heart journal, 42(48), 4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Kondo, Hidekazu, et al. "Effects of canagliflozin on human myocardial redox signalling: clinical implications." European heart journal vol. 42,48 (2021): 4947-4960. doi: https://doi.org/10.1093/eurheartj/ehab420
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420. PMID: 34293101; PMCID: PMC8691807.
Copy Download .nbib Format: NLM
Effects of canagliflozin on human myocardial redox signalling: clinical implications.

European heart journal

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C.
PMID: 34293101
Eur Heart J. 2021 Jul 19; doi: 10.1093/eurheartj/ehab420. Epub 2021 Jul 19.

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects,...

Cite
Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;doi: 10.1093/eurheartj/ehab420.
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., Oikonomou, E. K., Reus, E. M., Sayeed, R., Krasopoulos, G., Srivastava, V., Farid, S., Chuaiphichai, S., Shirodaria, C., Channon, K. M., Casadei, B., & Antoniades, C. (2021). Effects of canagliflozin on human myocardial redox signalling: clinical implications. European heart journal, . https://doi.org/10.1093/eurheartj/ehab420
Kondo, Hidekazu, et al. "Effects of canagliflozin on human myocardial redox signalling: clinical implications." European heart journal vol. (2021). doi: https://doi.org/10.1093/eurheartj/ehab420
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021 Jul 19; doi: 10.1093/eurheartj/ehab420. Epub 2021 Jul 19. PMID: 34293101.
Copy Download .nbib Format: NLM
Driving pressure during proportional assist ventilation: an observational study.

Annals of intensive care

Vaporidi K, Psarologakis C, Proklou A, Pediaditis E, Akoumianaki E, Koutsiana E, Chytas A, Chouvarda I, Kondili E, Georgopoulos D.
PMID: 30603960
Ann Intensive Care. 2019 Jan 03;9(1):1. doi: 10.1186/s13613-018-0477-4.

BACKGROUND: During passive mechanical ventilation, the driving pressure of the respiratory system is an important mediator of ventilator-induced lung injury. Monitoring of driving pressure during assisted ventilation, similar to controlled ventilation, could be a tool to identify patients at...

Cite
Vaporidi K, Psarologakis C, Proklou A, et al. Driving pressure during proportional assist ventilation: an observational study. Ann Intensive Care. 2019;9(1):1doi: 10.1186/s13613-018-0477-4.
Vaporidi, K., Psarologakis, C., Proklou, A., Pediaditis, E., Akoumianaki, E., Koutsiana, E., Chytas, A., Chouvarda, I., Kondili, E., & Georgopoulos, D. (2019). Driving pressure during proportional assist ventilation: an observational study. Annals of intensive care, 9(1), 1. https://doi.org/10.1186/s13613-018-0477-4
Vaporidi, Katerina, et al. "Driving pressure during proportional assist ventilation: an observational study." Annals of intensive care vol. 9,1 (2019): 1. doi: https://doi.org/10.1186/s13613-018-0477-4
Vaporidi K, Psarologakis C, Proklou A, Pediaditis E, Akoumianaki E, Koutsiana E, Chytas A, Chouvarda I, Kondili E, Georgopoulos D. Driving pressure during proportional assist ventilation: an observational study. Ann Intensive Care. 2019 Jan 03;9(1):1. doi: 10.1186/s13613-018-0477-4. PMID: 30603960; PMCID: PMC6314935.
Copy Download .nbib Format: NLM
Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study : Pressure support versus proportional ventilation during lower limb exercise in ventilated critically ill patients.

Annals of intensive care

Akoumianaki E, Dousse N, Lyazidi A, Lefebvre JC, Graf S, Cordioli RL, Rey N, Richard JM, Brochard L.
PMID: 28608135
Ann Intensive Care. 2017 Dec;7(1):64. doi: 10.1186/s13613-017-0289-y. Epub 2017 Jun 12.

BACKGROUND: Early exercise of critically ill patients may have beneficial effects on muscle strength, mass and systemic inflammation. During pressure support ventilation (PSV), a mismatch between demand and assist could increase work of breathing and limit exercise. A better...

Cite
Akoumianaki E, Dousse N, Lyazidi A, et al. Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study : Pressure support versus proportional ventilation during lower limb exercise in ventilated critically ill patients. Ann Intensive Care. 2017;7(1):64doi: 10.1186/s13613-017-0289-y.
Akoumianaki, E., Dousse, N., Lyazidi, A., Lefebvre, J. C., Graf, S., Cordioli, R. L., Rey, N., Richard, J. M., & Brochard, L. (2017). Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study : Pressure support versus proportional ventilation during lower limb exercise in ventilated critically ill patients. Annals of intensive care, 7(1), 64. https://doi.org/10.1186/s13613-017-0289-y
Akoumianaki, Evangelia, et al. "Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study : Pressure support versus proportional ventilation during lower limb exercise in ventilated critically ill patients." Annals of intensive care vol. 7,1 (2017): 64. doi: https://doi.org/10.1186/s13613-017-0289-y
Akoumianaki E, Dousse N, Lyazidi A, Lefebvre JC, Graf S, Cordioli RL, Rey N, Richard JM, Brochard L. Can proportional ventilation modes facilitate exercise in critically ill patients? A physiological cross-over study : Pressure support versus proportional ventilation during lower limb exercise in ventilated critically ill patients. Ann Intensive Care. 2017 Dec;7(1):64. doi: 10.1186/s13613-017-0289-y. Epub 2017 Jun 12. PMID: 28608135; PMCID: PMC5468357.
Copy Download .nbib Format: NLM
Patient-Ventilator Dyssynchrony.

Korean journal of critical care medicine

Antonogiannaki EM, Georgopoulos D, Akoumianaki E.
PMID: 31723652
Korean J Crit Care Med. 2017 Nov;32(4):307-322. doi: 10.4266/kjccm.2017.00535. Epub 2017 Nov 30.

In mechanically ventilated patients, assisted mechanical ventilation (MV) is employed early, following the acute phase of critical illness, in order to eliminate the detrimental effects of controlled MV, most notably the development of ventilator-induced diaphragmatic dysfunction. Nevertheless, the benefits...

Cite
Antonogiannaki EM, Georgopoulos D, Akoumianaki E. Patient-Ventilator Dyssynchrony. Korean J Crit Care Med. 2017;32(4):307-322doi: 10.4266/kjccm.2017.00535.
Antonogiannaki, E. M., Georgopoulos, D., & Akoumianaki, E. (2017). Patient-Ventilator Dyssynchrony. Korean journal of critical care medicine, 32(4), 307-322. https://doi.org/10.4266/kjccm.2017.00535
Antonogiannaki, Elvira-Markela, et al. "Patient-Ventilator Dyssynchrony." Korean journal of critical care medicine vol. 32,4 (2017): 307-322. doi: https://doi.org/10.4266/kjccm.2017.00535
Antonogiannaki EM, Georgopoulos D, Akoumianaki E. Patient-Ventilator Dyssynchrony. Korean J Crit Care Med. 2017 Nov;32(4):307-322. doi: 10.4266/kjccm.2017.00535. Epub 2017 Nov 30. PMID: 31723652; PMCID: PMC6786679.
Copy Download .nbib Format: NLM
Effects of canagliflozin on human myocardial redox signalling: clinical implications.

European heart journal

Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C.
PMID: 34293101
Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420.

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects,...

Cite
Kondo H, Akoumianakis I, Badi I, et al. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021;42(48):4947-4960doi: 10.1093/eurheartj/ehab420.
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., Oikonomou, E. K., Reus, E. M., Sayeed, R., Krasopoulos, G., Srivastava, V., Farid, S., Chuaiphichai, S., Shirodaria, C., Channon, K. M., Casadei, B., & Antoniades, C. (2021). Effects of canagliflozin on human myocardial redox signalling: clinical implications. European heart journal, 42(48), 4947-4960. https://doi.org/10.1093/eurheartj/ehab420
Kondo, Hidekazu, et al. "Effects of canagliflozin on human myocardial redox signalling: clinical implications." European heart journal vol. 42,48 (2021): 4947-4960. doi: https://doi.org/10.1093/eurheartj/ehab420
Kondo H, Akoumianakis I, Badi I, Akawi N, Kotanidis CP, Polkinghorne M, Stadiotti I, Sommariva E, Antonopoulos AS, Carena MC, Oikonomou EK, Reus EM, Sayeed R, Krasopoulos G, Srivastava V, Farid S, Chuaiphichai S, Shirodaria C, Channon KM, Casadei B, Antoniades C. Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J. 2021 Dec 21;42(48):4947-4960. doi: 10.1093/eurheartj/ehab420. PMID: 34293101; PMCID: PMC8691807.
Copy Download .nbib Format: NLM
Showing 13 to 23 of 23 entries